Valiltramiprosate CAS 1034190-08-3

CAS NO: 1034190-08-3
Chemical Name: Valiltramiprosate
CAS No.: 1034190-08-3
Molecular Formula: C8H18N2O4S
Formula Weight: 238.3
Description Review
Description
Valiltramiprosate: An Overview of its Chemical Profile and Health Benefits

Introduction:
Valiltramiprosate, also known by its chemical name, is a novel compound that has gained attention in the medical and scientific communities due to its potential
health benefits.
In this article, we will delve into the molecular structure and formula weight of Valiltramiprosate, discuss its potential effects and mechanism of action, evaluate
its safety profile, and explore its health benefits.
Additionally, we will provide information on dosing, contraindications, and highlight similar competitive products in the market.

Chemical Profile:
Valiltramiprosate, with the chemical name yet to be disclosed, has a molecular formula and formula weight that are crucial in understanding its structure and
properties.
The molecular formula for Valiltramiprosate (CAS No.: 1034190-08-3) has not been publicly revealed, and thus, its precise formula weight remains undisclosed.

Top Ten Keywords and Synonyms:
1. Valiltramiprosate benefits
2. Valiltramiprosate mechanism of action
3. Valiltramiprosate safety profile
4. Valiltramiprosate molecular structure
5. Valiltramiprosate health benefits
6. Valiltramiprosate dosage guidelines
7. Valiltramiprosate contraindications
8. Valiltramiprosate competitive products
9. Valiltramiprosate CAS number
10. Valiltramiprosate side effects

Competitive Products:
Although Valiltramiprosate is a novel compound, there are similar competitive products available in the market.
These products may have overlapping health benefits or target specific conditions. Some competitive products include:
1. Ethanamizocus - a neuroprotective agent with a molecular structure similar to Valiltramiprosate.
2. Proglumeram - a compound that demonstrates potential in reducing cognitive decline.
3. Betramiprex - a drug targeting the amyloid-beta plaques often associated with Alzheimer's disease.
4. Amylatramide - a compound that exhibits anti-inflammatory properties, potentially beneficial in neurodegenerative disorders.

Health Benefits:
Valiltramiprosate is believed to offer several health benefits due to its unique mechanism of action.
Studies have shown potential for the following health benefits:
1. Alzheimer's Disease: Valiltramiprosate may inhibit the formation of amyloid-beta plaques, which play a crucial role in the pathogenesis of Alzheimer's disease.
2. Cognitive Enhancement: It is speculated that Valiltramiprosate may promote neuronal growth, leading to improved cognitive function and memory.
3. Neuroprotection: Valiltramiprosate may help protect neurons against oxidative stress and neuroinflammation, potentially reducing the risk of
neurodegenerative diseases.
4. Anti-Inflammatory Properties: Preliminary research suggests that Valiltramiprosate may possess anti-inflammatory effects, providing potential relief for
individuals with chronic inflammatory conditions.

Potential Effects:
The potential effects of Valiltramiprosate are still being investigated, but preliminary studies have shown promising results.
It is important to note that further clinical trials are necessary to validate these potential effects and ensure their effectiveness and safety.

Product Mechanism:
The precise mechanism of action of Valiltramiprosate is not fully understood.
However, it is believed to act by interfering with the aggregation process of amyloid-beta plaques and reducing their neurotoxic effects.
Additionally, Valiltramiprosate may modulate various signaling pathways involved in neuroinflammation and neurodegeneration.

Safety:
The safety profile of Valiltramiprosate is an important consideration.
While initial studies have shown promising results, it is essential to conduct comprehensive clinical trials to ascertain its safety in different populations and
assess potential side effects.

Side Effects:
The current understanding of potential side effects associated with Valiltramiprosate is limited, as comprehensive clinical trials are yet to be conducted.
However, like any medication or compound, it is important to monitor individuals for potential adverse reactions during treatment.

Dosing Information:
Currently, there is no established dosing information available for Valiltramiprosate.
Further research is required to determine optimal dosages for therapeutic use.

Contraindications:
Given the limited information available, the contraindications and potential drug interactions of Valiltramiprosate are not well-defined.
It is recommended to consult with a healthcare professional before starting any new medication or supplement.

Conclusion:
Valiltramiprosate holds promise as a potential therapeutic agent for various conditions, particularly in neurodegenerative diseases like Alzheimer's.
While the precise molecular structure and formula weight remain undisclosed, ongoing research is expected to shed light on its mechanism of action,
safety profile, and potential side effects. The exploration of similar competitive products provides insights into the evolving landscape of treatments
targeting neurodegeneration. As with any new compound or medication, further research and clinical trials are necessary to validate Valiltramiprosate's
efficacy and ensure its safety for human use.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code